Michigan is in the national news because of a disturbing development in human fetal stem cell experimentation. Neuralstem, Inc. announced that it has received approval from the Food and Drug Administration to expand an amyotrophic lateral sclerosis (Lou Gehrig’s disease) Phase II study to the University of Michigan. The stem cells used in the study come from spinal cord tissue taken from a healthy, 8-week-old aborted baby. Phase I of the trial tested whether human fetal stem cells can safely be injected into the spinal cord. According to Neuralstem, the aim of Phase II is to obtain the maximum tolerated...